TLR3 agonists and proinflammatory antitumor activities

Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics

(2012) Danielle N. Van et al.   FASEB JOURNAL

Polyinosinic-Polycytidylic Acid Limits Tumor Outgrowth in a Mouse Model of Metastatic Lung Cancer

(2012) G. Forte et al.   JOURNAL OF IMMUNOLOGY

Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors

(2012) H. Shime et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3–IRF3 signaling and type I interferons in dendritic cells

(2012) Ce Wang et al.   VACCINE

Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer

(2011) Touko Inao et al.   BREAST CANCER RESEARCH AND TREATMENT

Anticancer function of polyinosinic-polycytidylic acid

(2011) Yu-sheng Cheng et al.   CANCER BIOLOGY & THERAPY

Toll-like Receptor 3–Mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance

(2010) Arnold I. Chin et al.   CANCER RESEARCH

Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC- -dependent mechanism

(2008) A. Paone et al.   CARCINOGENESIS

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

(2008) Nicholas Butowski et al.   JOURNAL OF NEURO-ONCOLOGY